A multi-omics biomarker partner needs 3 capabilities: ✅Integrated Study Design ✅Functional Validation ✅Quality Infrastructure Crown Bioscience connects data, biology, and quality planning before samples ever ship. Learn more about our services: okt.to/CbXxWp

Meet us at SITC 2026 Booth 609. We offer a complete suite of platforms for precise immunotherapy development like in vitro 2D/3D assays, pharmacology studies, and more. We're also showcasing 3 new scientific posters. Schedule a meeting in advance: okt.to/YAKl1S

Our IHC Biomarker Menu is searchable, allowing you to filter 400+ validated markers by category, species, and platform, then export your shortlist. Don’t see your target? Our labs can validate it - contact us today. Learn more: okt.to/7V2rwa

Crown Bioscience will be at the ESMO Congress in Spain, helping to shape the global oncology community and sharing expertise on the latest advancements in cancer research. If you are planning to attend, you can schedule a meeting in advance: okt.to/JPU6hK

🎙️Chris Dillon, Executive Director of In Vivo at Crown Bioscience’s San Diego site, talks about how model selection, engineering, and translational relevance come together to build studies that deliver actionable results. Listen to the full podcast: okt.to/JRwPUp

📍We're here at ELRIG Drug Discovery 2026! Visit us at Booth J04, 14–15 October 2026. Discover more about our cell therapies, next-generation ADC discovery with patient-derived models and our specialty translational biomarker laboratory capabilities.

Prostate cancer drug development is progressing into a more focused phase. Read our latest blog post for insights into the next wave prostate cancer therapies: okt.to/IojGzn

Join Crown Bioscience at ELRIG Drug Discovery 2026, Booth J04, 14–15 October 2026! Connect with us to discuss our translational models and platforms that can accelerate your pipeline. Schedule a meeting with us to explore opportunities: okt.to/v9l15D @ELRIG_SCIENCE

Our Boston Symposium brought together brilliant scientific minds. A huge thank you to everyone! 🙌 📍 Up next: Cambridge! Join us on October 21 as UK and European research communities unite to advance oncology drug discovery. Secure your spot today: okt.to/bRipzc

250+ organoid models make a difference. OrganoidXplore™ offers well-characterized PDO and PDXO models, diverse panel options, and advanced biomarker analysis. Oncology teams can improve model selection, data reliability, and workflow efficiency. crownbio.com/organoidxplore

Join us on October 21st in Cambridge for our oncology drug discovery symposium, featuring UK and European research communities. Enjoy presentations, discussions, and networking with free snacks and drinks. Space is limited, so reserve your spot now! okt.to/ZFfyhB

By generating more predictive, reproducible, and clinically relevant data, our Organoid Model Database reduces the risk of clinical failure – helping you to make faster, smarter research decisions. Advance your oncology research with Organoids: okt.to/2UreBE

Learn how to structure IO combination studies by mapping intervention points across the cancer immunity cycle, selecting model systems that reflect the immune interaction being tested, and layering biomarker evidence to de-risk translational decisions. okt.to/rHuvEh

What makes the UK such a strong ecosystem for cancer drug development? Collaboration. Listen to the podcast to hear the value of working across the wider research community, sharing knowledge and creating opportunities for collaboration both in the UK. okt.to/ZX3Ish

📣Join us at the Howard Theatre in Cambridge on 21st October 2026 (9:30 AM – 4:30 PM) for a symposium bringing together UK and European researchers to explore the latest in oncology drug discovery. Spaces are limited: register now! okt.to/Hq1ocf

In this article, we explore how DMPK can serve as a powerful translational framework for identifying risk, optimizing candidates, guiding clinical dose selection, & increasing the probability that promising therapies reach patients. okt.to/1nby7O

This month’s featured gastric model series brings together matched PDX and PDXO models. These models provide a way to connect biomarker expression with ADC activity across in vitro and in vivo systems. okt.to/jfrNIP

The BMN regulates hematopoietic stem cells and supports healthy blood cell production. When this complex microenvironment is disrupted, it can contribute to tumor progression, drug resistance, and metastasis. okt.to/8LpVQa

Our cutting-edge 3D bone marrow niche in vitro models advance hematological cancer research by accurately recapitulating the tumor microenvironment – giving you more reliable and predictive results. okt.to/kbUV3u

In this study from Crown Bioscience, a panel of AML PDX models with multiple gene alterations was established to support the development of new therapies. See the findings for yourself: okt.to/lx1dsA